Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of 7+3 + Gemtuzumab Ozogamicin vs. 7+3 + Venetoclax in Newly Diagnosed CBF-AML
NCT06917911Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in Core-binding factor acute myeloid leukemia (CBF-AML) comparing Regimen 1 (gemtuzumab ozogamicin 7+3) with Regimen 2 (Venetoclax, 7+3) (2 arms). Primary endpoint: Complete remission without measurable residual disease at 28 days. Started Sep 2026; status: recruiting.
02
Drugs
venetoclaxgemtuzumab ozogamicin
03
Conditions
Core-binding factor acute myeloid leukemia (CBF-AML)
Beyond the preview
Go deeper on NCT06917911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917911.